Zymeworks Achieves Key Milestones in Global Development: NMPA Acceptance of BLA for Zanidatamab in China and Inclusion in Nasdaq Biotechnology Index’
VANCOUVER, British Columbia, June 10, 2024 Zymeworks Inc. (Nasdaq: ZYME), a pioneering clinical-stage biotechnology company, is making significant strides in advancing its robust pipeline of cutting-edge biotherapeutics aimed at enhancing the treatment of challenging diseases. Recently, the company announced a major accomplishment as the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China has accepted the Biologics License Application (BLA) for zanidatamab. This innovative therapy is intended for the second-line treatment of HER2-positive biliary tract cancer (BTC), an aggressive disease with limited treatment options.
Breakthrough in China: NMPA Acceptance
The NMPA’s acceptance of the BLA for zanidatamab marks a pivotal moment for Zymeworks, providing a beacon of hope for patients in China suffering from HER2-positive BTC. Under the terms of the license and collaboration agreement with BeiGene for the Asia Pacific region, this milestone triggers an $8 million payment to Zymeworks. Furthermore, Zymeworks stands to receive up to an additional $164 million through subsequent milestones, coupled with royalties on product sales, bolstering the company’s financial position and enabling further innovation.
This acceptance by the NMPA underscores our commitment to bringing transformative therapies to patients globally, said Dr. Ali Tehrani, CEO of Zymeworks. We are excited about the potential of zanidatamab to address the unmet medical needs in biliary tract cancer and look forward to collaborating with BeiGene to make this treatment accessible in China.
Evolution of a Biotech Giant: Inclusion in Nasdaq Biotechnology Index
Adding to its recent achievements, Zymeworks announced on December 15, 2023, its inclusion in the Nasdaq Biotechnology Index (NBI). Effective as of December 18, 2023, this inclusion signifies recognition of Zymeworks’ innovative contributions and its potential for growth within the biotechnology sector. The NBI comprises securities of Nasdaq-listed companies classified as either biotechnology or pharmaceutical, highlighting entities that play a pivotal role in scientific advancement and medical innovation.
Joining the Nasdaq Biotechnology Index is a testament to the scientific rigor and market potential of our therapeutic candidates, Dr. Tehrani added. This inclusion is a significant milestone that reflects the increasing recognition of our work and positions us strategically within the biotechnology investment community.
Creating a Global Impact
With these significant milestones, Zymeworks is positioning itself at the forefront of biotechnological innovation. The acceptance of the BLA for zanidatamab in China is not only a leap forward for the company but also a promising development for patients battling HER2-positive biliary tract cancer. By leveraging strategic partnerships, such as the one with BeiGene, and advancing its diverse pipeline of multifunctional biotherapeutics, Zymeworks continues to enhance its global impact.
The company’s inclusion in the Nasdaq Biotechnology Index further endorses its market credibility, potentially attracting additional investment and providing a platform for sustained growth. These developments mark an exciting new chapter for Zymeworks, as it continues to pioneer novel treatments and strive towards improving the standard of care for patients worldwide.
As Zymeworks amplifies its reach through collaborative efforts and innovative breakthroughs, it remains resolute in its mission: to develop and deliver transformative therapies that make a tangible difference in the lives of patients dealing with difficult-to-treat diseases.
Comments